Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer

Molecular differences in tumor locations may contribute to the sidedness-specific response to cetuximab in metastatic colorectal cancer (mCRC). We investigated genes associated with the response to cetuximab treatment depending on tumor sidedness. Our study included 77 patients with mCRC (13/63, rig...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Cancer Ther
Auteurs principaux: Sunakawa, Yu, Mogushi, Kaoru, Lenz, Heinz-Josef, Zhang, Wu, Tsuji, Akihito, Takahashi, Takehiro, Denda, Tadamichi, Shimada, Ken, Kochi, Mitsugu, Nakamura, Masato, Kotaka, Masahito, Segawa, Yoshihiko, Tanioka, Hiroaki, Negoro, Yuji, Moran, Miriana, Astrow, Stephanie H., Hsiang, Jack, Stephens, Craig, Fujii, Masashi, Ichikawa, Wataru
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497846/
https://ncbi.nlm.nih.gov/pubmed/30275242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0694
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires